The Relationship between Previous Tuberculosis Treatment and HIV Status with Multidrug-Resistant Tuberculosis

Dyan Kunthi Nugrahaeni, Salma Zaqiya


Multidrug-resistant tuberculosis (MDR-TB) is becoming major public health issues in the world. Among the causes are history of previous TB treatment and increased co-infection of TB-HIV (Human Immunodeficiency Virus). This study aimed to identify the relationship between history of previous TB treatment and HIV status with MDR-TB. This is a case control study. The sample case was patients with MDR-TB, while sample control was patient who have drug-sensitive TB. Secondary data was obtained from patient medical records and laboratory results at Rotinsulu Pulmonary Hospital Bandung. Data were analyzed using chi-square. Multiple logistic regression was used to identify the dominant factor that influence the occurrence of MDR-TB. This study showed that the history of previous TB treatment was statistically significant with MDR-TB (p value= 0.001; OR= 18.889; 95% CI= 4.093-87.172) and it is the dominant factor that influence MDR-TB (p value= 0.0001; OR= 56.84; 95% CI= 6.9- 468.87). HIV infection at control group (who contracted drug-sensitive TB) was 26.1% (p value= 0.022). This finding suggested that HIV testing should be performed to each TB and MDR-TB patients and increased collaboration TB-HIV program between the other health care facilities should ensue. Drug sensitivity testing should be conducted at the start of TB treatment for patients with previous TB treatment and TB-HIV co-infection.


MDR-TB, history of previous TB treatment, HIV status

Full Text:



Burhan, E. (2010) ‘Peran International Standards for Tuberculosis Care dalam Pencegahan MDR’, Jurnal Tuberkulosis Indonesia, 7, pp. 12–15.

Dean, A., Cox, H. and Zignol, M. (2017) ‘Epidemiology of Drug-Resistant Tuberculosis’, Advances in experimental medicine and biology, 1019, pp. 209–220.

Fadila, R. N., and Riono, P. (2014) ‘Pengaruh Rejimen terhadap Ketidakpatuhan Berobat Tuberkulosis’, Jurnal Kesehatan Masyarakat Nasional, 9, pp. 107–112.

Faustini (2006) ‘Risk Factors for Multidrug Resistant Tuberculosis in Europe: A Systematic Review’, pp. 158–163.

Hanf, M., Adenis, A., Coippie, P., Carme, B., Nacher, M. (2012) ‘The impact of corruption on multidrug-resistant tuberculosis: A quantitative assessment’, European Respiratory Journal, 40(3), pp. 792–793.

Louw, G. E., Warren R. M., Pittius, V. G., McEvoy C. R. E., Helden, V.P.D. (2009) ‘MINIREVIEW A Balancing Act : Efflux/Influx in Mycobacterial Drug Resistance’, Antimicrobial agent and chemotherapy, 53(8), pp. 3181–3189.

Nugrahaeni, D. K., and Malik, U. S. (2013) ‘Analisis Penyebab Resistensi Obat Anti Tuberkulosis’, Jurnal Kesehatan Masyarakat, 8(2), pp. 113–120.

Sarwani, D., Nurlaela, S. and Zuhrotul, I. (2012) ‘Faktor Risiko Multidrug Resistant Tuberculosis (Mdr-Tb)’, Jurnal Kesehatan Masyarakat, 8(1), pp. 60–66.

Sharma, S. and Mohan, A. (2004) ‘Multidrug-resistant tuberculosis’, Indian J Med Res, pp. 354–376.

Skrahina, A. (2012) ‘Multidrug Resistant Tuberculosis in Belarus: The Size of The Problem and Associated Risk Factors’, Bulletin of The World Helath Organization, pp. 36–45.

Soepandi (2010) ‘Diagnosis dan penatalaksaaan TB-MDR’, Cermin Dunia Kedokteran, pp. 497–500.

Soepandi, P. (2012) ‘Diagnosis dan Faktor yang mempengaruhi terjadinya TB-MDR’, Jurnal Tuberkulosis Indonesia, 8.

Suchindran, S., Brouwer, E. S. and Van Rie, A. (2009) ‘Is HIV Infection a Risk Factor for Multi-Drug Resistant Tuberculosis? A Systematic Review’, PLoS ONE. Edited by B. Marais. Public Library of Science, 4(5), p. e5561.


  • There are currently no refbacks.